Estriol‐mediated neuroprotection in multiple sclerosis localized by voxel‐based morphometry

INTRODUCTION: Progressive gray matter (GM) atrophy is a hallmark of multiple sclerosis (MS). Cognitive impairment has been observed in 40%–70% of MS patients and has been linked to GM atrophy. In a phase 2 trial of estriol treatment in women with relapsing–remitting MS (RRMS), higher estriol levels...

Descripción completa

Detalles Bibliográficos
Autores principales: MacKenzie‐Graham, Allan, Brook, Jenny, Kurth, Florian, Itoh, Yuichiro, Meyer, Cassandra, Montag, Michael J., Wang, He‐Jing, Elashoff, Robert, Voskuhl, Rhonda R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160650/
https://www.ncbi.nlm.nih.gov/pubmed/30144306
http://dx.doi.org/10.1002/brb3.1086

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160650/
https://www.ncbi.nlm.nih.gov/pubmed/30144306
http://dx.doi.org/10.1002/brb3.1086

Ejemplares similares